Abstract: An electrical connection testing device is provided with a connector holder (12), first and second probe holders (13, 14) which are successively arranged such that the connector holder (12) and the second probe holder are movable toward and away from the connector holder (12). A pushing mechanism (18) for pushing a receiving surface (14d) of the second probe holder (14) at the opposite side from the connector holder (12) is so coupled with the second probe holder (14) as to be movable toward and away from the second probe holder (14). The second probe holder (14) and the connector holder (12) are moved according to the movement of the pushing mechanism (18), thereby being positioned at testing positions (P1) where probes (16, 17) are inserted into testing holes (1a) of a connector (C) from opposite sides or at retracted positions (P2) where the connector can be taken out of a connector holder (12).

Abstract: The compound of the present invention possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e,g., sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea sydrome, multilocular ovary sydrome, pimples etc, or as a pregnancy regulator (e.g., contraceptive), infertility remedy or menstruation regulator.

Abstract: There is disclosed a semiconductor light emitting element formed by selective growth and being high in light emitting efficiency, in which at least one GaN-based layer grown by ELO is stacked/formed on a sapphire substrate, and a fluorescent substance for converting an ultraviolet light to a visible light is contained in a selective growth mask material layer for use in this case. Since this fluorescent substance converts the ultraviolet light to the visible light, a binding efficiency of the ultraviolet light to the fluorescent substance is enhanced in either one of a center light emitting type and UV light emitting type of light emitting elements. By further containing the fluorescent substance into a passivation film, the efficiency is further enhanced.

Abstract: The compound of the present invention possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e.g., sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea syndrome, multilocular ovary syndrome, pimples etc, or as a pregnancy regulator (e.g., contraceptive), infertility remedy or menstruation regulator.

Abstract: The present invention relates to a pharmaceutical luteinizing hormone releasing hormone agonist in combination with a luteinizing hormone releasing hormone antagonist. By using a luteinizing hormone releasing hormone agonist and a luteinizing hormone releasing hormone antagonist in combination, the transient exacerbation with elevation of serum testosterone and estrogen owing to the pituitary-gonadotropic action (acute action) manifested immediately following an initial dose of the luteinizing hormone releasing hormone agonist can be successfully obviated.

Abstract: The present thienopyridine derivatives and composition having gonadotropin-releasing hormone antagonistic activity are useful as prophylactic or therapeutic agents for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g.

Abstract: A nitride compound semiconductor light emitting element comprises a substrate, a nitride compound semiconductor n-type layer, a mask layer having a predetermined opening, a nitride compound semiconductor buffer layer epitaxially grown on said n-type layer exclusively at said opening. The buffer layer has a recess on its top face so that a thickness of said buffer layer is thinner above a central portion of the opening and thicker above edge portions of the opening. A nitride compound semiconductor active layer is selectively formed on the recess of the buffer layer to be thicker at the central portion of the recess and thinner at the edges of the recess. A nitride compound semiconductor burying layer overlays the mask layer and the active layer to cover the active layer.

Abstract: The prolactin production inhibition agent of the present invention containing a condensed cyclic compound, which is characterized by containing a condensed bicyclic structure of an optionally substituted homo or hetero 5- to 7-membered ring with an optionally substituted homo or hetero 5- to 7-membered ring, or a salt thereof, can be used, as a medicine, for the prophylaxis or therapy of diseases accompanied with an excess prolactin production or diseases having enhanced reactivity with prolactin, or is useful for inhibiting puerperal lactation, and also useful as a prophylactic or therapeutic agent of galactorrhea, hyperprolactinemic ovulation disturbance, amenorrhea-galactorrhea syndrome, prolactinoma, and besides, interbrain tumor, and acromegaly, pituitary gigantism.

Abstract: According to this invention, antibodies which are useful and novel in that they have binding specificity to .beta.-amyloids or derivatives thereof, namely recognize the N-terminal, the C-terminal or central portions of the .beta.-amyloids, respectively, were obtained. By combining these antibodies, determination methods by which the .beta.-amyloids could be determined sensitively and specifically are provided. These determination methods are useful for diagnosis of diseases to which the .beta.-amyloids or their derivatives are related (for example, Alzheimer's disease), and the antibodies of this invention are useful for the development of preventive-therapeutic compositions for Alzheimer's disease.

Abstract: An organic bismuth derivative represented by formula (I) or its salt: ?wherein X.sup.1 is YNR.sup.1 R.sup.2 (wherein Y is --SO.sub.2 -- or --C(O)--, R.sup.1 is a C.sub.3-6 alkyl group which have from 2 to 5 hydroxyl groups which may be protected, and R.sup.2 is a hydrogen atom, a C.sub.1-6 alkyl group or a C.sub.1-5 acyl group which may have from 1 to 5 hydroxyl groups which may be protected, or R.sup.1 and R.sup.2, together with each other, represent a C.sub.2-6 cyclic alkylene which may have from 1 to 4 hydroxyl groups which may be protected), and each of X.sup.2 and X.sup.3 is, independently of each other, a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkylsulfonyl group, a C.sub.1-4 alkylcarbonyl group, a nitro group, a cyano group or the same as defined for X.sup.1 !.

Abstract: According to this invention, antibodies which are useful and novel in that they have binding specificity to .beta.-amyloids or derivatives thereof, namely recognize the N-terminal, the C-terminal or central portions of the .beta.-amyloids, respectively, were obtained. By combining these antibodies, determination methods by which the .beta.-amyloids could be determined sensitively and specifically are provided. These determination methods are useful for diagnosis of diseases to which the .beta.-amyloids or their derivatives are related (for example, Alzheimer's disease), and the antibodies of this invention are useful for the development of preventive-therapeutic compositions for Alzheimer's disease.

Abstract: Disclosed are a monoclonal antibody having affinity for PACAP, a partial peptide thereof, a precursor thereof or VIP; a hybridoma cell which produces the above monoclonal antibody; and an immunoassay for assaying PACAP by a competitive method or a sandwich method using the above antibody, whereby PACAP can be specifically detected with high sensitivity.

Abstract: An apparatus for controlling rotation of a spindle motor includes a lock detection unit, a memory unit, a comparison unit, and a control unit. When the lock detection unit detects the lock state of the time base servo loop, a voltage corresponding to the frequency of a read RF signal is stored in the memory unit. When the control unit detects that the rotation velocity of the spindle motor greatly deviates from a normal rotation velocity, it effects a control so as to accelerate or decelerate the spindle motor in dependency upon a compared result of the comparison unit which makes a comparison between a voltage corresponding to the frequency of the read RF signal and a voltage stored in the memory unit.

Abstract: Disclosed are monoclonal antibodies having an affinity for endothelin-3 or a precursor thereof; a hybridoma cell which produces the monoclonal antibody; and an immunoassay of endothelin-3 and big endothelin-3, a precursor of endothelin-3, by a sandwich method or a competitive method. The monoclonal antibodies can be used as strong antagonists for endothelin-3 in various endothelin-3-related diseases, and the immunoassays make it possible to determine endothelin-3 and big endothelin-3 with high sensitivity.

Abstract: A control circuit of a tray loading apparatus determines, according to a disc size and a tray moving direction, a time during which to control the motor at a constant speed. When the specified time has elapsed after the motor was started, the control circuit produces a pulse-width modulated output to slowly lower the motor speed, eliminating impact noise when the tray strikes a stopper. This motor deceleration time is measured. When the measured deceleration time disagrees with a preset or previously detected target deceleration time, the difference is either added to or subtracted from a constant-speed motor operation time and the resultant value is taken as the next target time for constant-speed motor operation. In this way, by changing the time during which the motor is driven at a constant speed, any variations in the tray moving speed as might occur from varying loads on the motor are absorbed to keep the motor deceleration time and decelerating speed unchanged, thus making the tray motion smooth.

Abstract: A control circuit of a tray loading apparatus determines, according to a disc size and a tray moving direction, a time during which to control the motor at a constant speed. When the specified time has elapsed after the motor was started, the control circuit produces a pulse-width modulated output to slowly lower the motor speed, eliminating impact noise when the tray strikes a stopper. This motor deceleration time is measured. When the measured deceleration time disagrees with a preset or previously detected target deceleration time, the difference is either added to or subtracted from a constant-speed motor operation time and the resultant value is taken as the next target time for constant-speed motor operation. In this way, by changing the time during which the motor is driven at a constant speed, any variations in the tray moving speed as might occur from varying loads on the motor are absorbed to keep the motor deceleration time and decelerating speed unchanged, thus making the tray motion smooth.

Abstract: A motor drive circuit for a radio-controlled model capable of readily varying any desired part of inclination of the input-output characteristics with a highly simplified circuit arrangement. The motor drive circuit includes an element for converting a signal corresponding to control condition into a digital signal and subjecting the digital signal to weighing processing for every bit thereof.

Abstract: An immunochemical assay of human carcinoembryonic antigen (CEA), comprising the use of an antibody supported on a carrier and an antibody labelled with peroxidase by coupling by means of a compound of the formula: ##STR1## wherein n is an integer of 0 to 5 and R is a chemical bond or a divalent 6-membered cyclic hydrocarbon residue, in which at least one of said antibodies is a monoclonal antibody. The assay can be conducted with high sensitivity by simple and easy operation in clinical laboratories.

Abstract: A motor servo system is disclosed which is capable of accomplishing the precise control of a set point of a mechanical element to be controlled without particularly considering the mechanical connecting condition between a motor and the mechanical element and being readily accommodated to a variation of the set point and a variation of overshoot due to a variation of load. The motor servo system is constructed in a manner such that a controlled set point of a controlled element such as a mechanical element is independently set by means of a time signal generating section preceding a servo circuit section.